切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2013, Vol. 02 ›› Issue (01) : 11 -17. doi: 10.3877/cma.j.issn.2095-3216.2013.01.003

专家论坛

儿童激素抵抗、依赖及复发肾病综合征的治疗
徐虹1,(), 李国民1, 龚一女1, 刘佳璐1   
  1. 1.201102 上海,复旦大学附属儿科医院
  • 出版日期:2013-02-15
  • 通信作者: 徐虹

Treatment of steroid-resistant, steroid-dependent and relapse nephrotic syndrome in children

Hong XU1,(), Guo-min LI1, Yi-nü GONG1, Jia-lu LIU1   

  1. 1.Children's Hospital of Fudan University, Shanghai 201102, China
  • Published:2013-02-15
  • Corresponding author: Hong XU
引用本文:

徐虹, 李国民, 龚一女, 刘佳璐. 儿童激素抵抗、依赖及复发肾病综合征的治疗[J/OL]. 中华肾病研究电子杂志, 2013, 02(01): 11-17.

Hong XU, Guo-min LI, Yi-nü GONG, Jia-lu LIU. Treatment of steroid-resistant, steroid-dependent and relapse nephrotic syndrome in children[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2013, 02(01): 11-17.

原发性肾病综合征(PNS)是儿童最常见的肾小球疾病。糖皮质激素治疗PNS 始于20 世纪50年代,并一直是国内外治疗PNS公认的首选药物。80% ~ 90%的PNS患儿初始激素治疗可获得完全缓解,其中10% ~ 20%不复发,10% ~ 20%为非频复发,40% ~ 50%为频复发(FRNS)或激素依赖(SDNS)。约有1/3的FRNS或SDNS患儿因长期或反复使用激素而出现严重的副作用,如生长抑制、高血压、糖尿病、骨质疏松、青光眼、白内障,甚至失明等。10% ~ 20%的PNS儿童表现为耐药(SRNS),超过半数的SRNS儿童在10年内会进展为终末期肾病(ESRD)。因此,FRNS、SDNS和SRNS儿童成为了临床关注的主要对象。笔者系统回顾了近年来国内外关于儿童肾病综合征临床治疗研究、Mate分析和国内外关于肾病综合征治疗指南的文献,对FRNS、SDNS和SRNS糖皮质激素、免疫抑制剂及其他药物的治疗效果进行综合分析,以供临床儿科医师参考。

Primary nephrotic syndrome (PNS) is the most common glomerular disease in children.Treatment of glucocorticoid (GC) for PNS began in 1950'. GC is always the first line drug for PNS since then. 80% to 90% of the children with PNS respond to steroid treatment, among which, 10% to 20% have no relapse, 10% to 20% show infrequent relapse, 40% to 50% present with frequent relapse nephrotic syndrome (FRNS) or steroid dependence nephrotic syndrome (SDNS). 1/3 children with frequent relapse or steroid dependent SDNS show serious side effect because of prolonged and repeated use of GC, such as growth inhibition, hypertension, diabetes, osteoporosis, glaucoma, cataract, and even blindness. 10% to 20% of the children with PNS have steroid resistance nephrotic syndrome (SRNS), and more than half of the patients progress to end-stage renal disease nephrotic syndrome (ESRD) within 10 years. Therefore,we should pay more attention to children with FRNS, SDNS and SRNS. We reviewed most literatures on clinical trial, meta-analysis and guideline in treatment of NS. We summarized treatment of FRNS, SDNS and SRNS in children for pediatrics or children nephrologists.

表1 GRADE 证据质量4 个等级含义(2011 版)
表2 GRADE 推荐强度的定义
1
Lennon R, Watson L, Webb NJA. Nephrotic syndrome in children[J]. Paediatr and Child Health. 2010, 20(1): 36-42.
2
Sinha A, Bagga A. Nephrotic syndrome [J]. Indian J Pediatr,2012, 79(8): 1045-1055.
3
Ernould S, Godron A, Nelson JR, et al. Idiopathic nephrotic syndrome in children: Incidence, clinical presentation, and outcome in the county of Gironde, France [J]. Arch Pediatr, 2011,18(5): 522-528.
4
Esfahani ST, Madani A, Asgharian F, et al. Clinical course and outcome of children with steroid-sensitive nephrotic syndrome [J].Pediatr Nephrol, 2011, 26(7): 1089-1093.
5
Greenbaum LA, Benndorf R, Smoyer WE. Childhood nephrotic syndrome--current and future therapies [J]. Nat Rev Nephrol,2012, 8(8): 445-458.
6
Davin JC, Rutjes NW. Nephrotic syndrome in children: from bench to treatment [J]. Int J Nephrol, 2011, 2011: 372304.
7
van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome [J]. Pediatr Nephrol, 2011, 26(6): 881-892.
8
Mehls O, Hoyer PF. Dosing of glucocorticosteroids in nephrotic syndrome [J]. Pediatr Nephrol, 2011, 26(12): 2095-2098.
9
Roberti I, Vyas S. Long-term outcome of children with steroidresistant nephrotic syndrome treated with tacrolimus [J]. Pediatr Nephrol, 2010, 25(6): 1117-1124.
10
中华医学会儿科分会肾脏病学组. 激素敏感、复发或依赖肾病综合征诊治循证指南 [J]. 中华儿科杂志, 2009,47(3): 167-169.
11
中华医学会儿科分会肾脏病学组.儿童常见肾脏疾病诊治循证指南(试行)(三):激素耐药型肾病综合征诊治指南[J]. 中华儿科杂志, 2010, (1): 72-75.
12
Lombel RM, Hodson EM, Gipson DS. Treatment of steroidresistant nephrotic syndrome in children: new guidelines from KDIGO [J]. Pediatr Nephrol, 2012, 28(3): 409-414.
13
Lombel RM, Gipson DS, Hodson EM. Treatment of steroidsensitive nephrotic syndrome: new guidelines from KDIGO [J].Pediatr Nephrol, 2012, 28(3): 415-426.
14
中华医学会儿科分会肾脏病学组. 诊断及治疗小儿肾小球疾病的临床分类. 小儿肾小球疾病的临床分类、诊断及治疗[J].中华儿科杂志, 2001, 39(12): 476-477.
15
van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome [J]. Pediatr Nephrol, 2011, 26(6): 881-892.
16
Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children [J/CD]. Cochrane Database Syst Rev, 2010, 10(11): 3594.
17
任献国,刘光陵,夏正坤,等. 儿童肾病综合征肾组织病理光镜和免疫荧光分型的关系[J]. 临床儿科杂志, 2012, 30(2): 147-149.
18
Guyatt GH, Oxman AD, Schunemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology [J]. J Clin Epidemiol, 2011, 64(4): 380-382.
19
Meerpohl JJ, Langer G, Perleth M, et al. GRADE guidelines: 3.Rating the quality of evidence (confidence in the estimates of effect) [J]. Z Evid Fortbild Qual Gesundhwes, 2012, 106(6): 449-456.
20
Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children [J/CD]. Cochrane Database Syst Rev, 2007, (4): 1533.
21
Mattoo TK, Mahmoud MA. Increased maintenance corticosteroids during upper respiratory infection decrease the risk of relapse in nephrotic syndrome [J]. Nephron, 2000, 85(4): 343-345.
22
Abeyagunawardena AS, Trompeter RS. Increasing the dose of prednisolone during viral infections reduces the risk of relapse in nephrotic syndrome: a randomised controlled trial [J]. Arch Dis Child, 2008,93(3): 226-228.
23
Gulati A, Sinha A, Sreenivas V, et al. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial [J]. Clin J Am Soc Nephrol, 2011, 6(1): 63-69.
24
Elzouki A Y, Jaiswal O P. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood.Effect on remission, statural growth, obesity, and infection rate [J].Clin Pediatr (Phila),1988, 27(8): 387-392.
25
Srivastava R N, Vasudev A S, Bagga A, et al. Long-term, lowdose prednisolone therapy in frequently relapsing nephrotic syndrome [J]. Pediatr Nephrol,1992, 6(3): 247-250.
26
El-Husseini A, El-Basuony F, Mahmoud I, et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome:a single-centre experience [J]. Nephrol Dial Transplant, 2005,20(11): 2433-2438.
27
Hamed R M. Treatment of idiopathic nephrotic syndrome with cyclosporin A in children [J]. J Nephrol, 1997, 10(5): 266-270.
28
Ghiggeri G M, Catarsi P, Scolari F, et al. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label,nonrandomized, retrospective study [J]. Clin Ther, 2004, 26(9):1411-1418.
29
Sinha M D, Macleod R, Rigby E, et al. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus [J]. Nephrol Dial Transplant, 2006, 21(7): 1848-1854.
30
Wang W, Xia Y, Mao J, et al. Treatment of tacrolimus or cyclosporine A in children with idiopathic nephrotic syndrome[J].Pediatr Nephrol,2012,27(11):2073-2079.
31
曹琦,黄文彦,徐虹,等. 长疗程环孢素A治疗儿童激素耐药型肾病综合征的疗效和预后 [J]. 中华儿科杂志, 2008, 46(9):698-701.
32
Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial [J]. Am J Kidney Dis, 2009, 53(5): 760-769.
33
Ruf R G, Lichtenberger A, Karle S M, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome [J]. J Am Soc Nephrol, 2004,15(3): 722-732.
34
Malina M, Cinek O, Janda J, et al. Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation [J]. Pediatr Nephrol, 2009, 24(10): 2051-2053.
35
Gellermann J, Stefanidis C J, Mitsioni A, et al. Successful treatment of steroid-resistant nephrotic syndrome associated with WT1 mutations [J]. Pediatr Nephrol, 2010, 25(7):1285-1289.
36
Bensman A, Niaudet P. Non-immunologic mechanisms of calcineurin inhibitors explain its antiproteinuric effects in genetic glomerulopathies [J]. Pediatr Nephrol, 2010, 25(7): 1197-1199.
37
Latta K, von Schnakenburg C, Ehrich J H. A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children [J]. Pediatr Nephrol, 2001, 16(3): 271-282.
38
孙嫱,沈颖. Meta 分析评价环磷酰胺对儿童肾病综合征的治疗作用[J]. 中华儿科杂志, 2006, 44(3): 199-201.
39
Hodson EM, Willis NS, Craig JC. Non-corticosteroid treatment for nephrotic syndrome in children [J/CD]. Cochrane Database Syst Rev, 2008, 23(1): CD002290.
40
Children I S O K. Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children [J]. Lancet,1974, 24, 2(7878): 423-427.
41
Tarshish P, Tobin J N, Bernstein J, et al. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children [J].Pediatr Nephrol, 1996, 10(5): 590-593.
42
Afzal K, Bagga A, Menon S, et al. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome [J]. Pediatr Nephrol, 2007, 22(12): 2059-2065.
43
Gellermann J, Querfeld U. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil [J]. Pediatr Nephrol, 2004, 19(1): 101-104.
44
Bagga A, Hari P, Moudgil A, et al. Mycophenolate mofetil and prednisolone therapy in children with steroid-dependent nephrotic syndrome [J]. Am J Kidney Dis, 2003, 42(6): 1114-1120.
45
Li Z, Duan C, He J, et al. Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome [J]. Pediatr Nephrol, 2010, 25(5): 883-888.
46
de Mello VR, Rodrigues MT, Mastrocinque TH, et al.Mycophenolate mofetil in children with steroid/cyclophosphamideresistant nephrotic syndrome [J]. Pediatr Nephrol, 2010, 25(3):453-460.
47
Gargah TT, Lakhoua MR. Mycophenolate mofetil in treatment of childhood steroid-resistant nephrotic syndrome [J]. J Nephrol,2011, 24(2): 203-207.
48
Guigonis V, Dallocchio A, Baudouin V, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome:a multicentric series of 22 cases [J]. Pediatr Nephrol, 2008, 23(8):1269-1279.
49
Ravani P, Magnasco A, Edefonti A, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial [J]. Clin J Am Soc Nephrol, 2011, 6(6): 1308-1315.
50
Sun L, Xu H, Cao Q, et al. Efficacy of rituximab therapy in children with refractory nephrotic syndrome: A prospective observational study in Shanghai [J]. World J Pediatr, 2013. [Epub ahead of print]
51
Ito S, Kamei K, Ogura M, et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome [J]. Pediatr Nephrol, 2011,26(10): 1823-1828.
52
Magnasco A, Ravani P, Edefonti A, et al. Rituximab in children with resistant idiopathic nephrotic syndrome [J]. J Am Soc Nephrol, 2012, 23(6): 1117-1124.
53
Yoshioka K, Ohashi Y, Sakai T, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome [J]. Kidney Int, 2000, 58(1): 317-324.
54
Kemper MJ, Amon O, Timmermann K, et al. The treatment with levamisole of frequently recurring steroid-sensitive idiopathic nephrotic syndrome in children [J]. Dtsch Med Wochenschr,1998, 123(9): 239-243.
55
Sumegi V, Haszon I, Ivanyi B, et al. Long-term effects of levamisole treatment in childhood nephrotic syndrome [J]. Pediatr Nephrol, 2004, 19(12): 1354-1360.
56
Fu LS, Shien CY, Chi CS. Levamisole in steroid-sensitive nephrotic syndrome children with frequent relapses and/or steroid dependency: comparison of daily and every-other-day usage [J].Nephron Clin Pract, 2004, 97(4): c137-c141.
57
Madani A, Isfahani S T, Rahimzadeh N, et al. Effect of levamisole in steroid-dependent nephrotic syndrome [J]. Iran J Kidney Dis,2010, 4(4): 292-296.
58
Levamisole for corticosteroid-dependent nephrotic syndrome in childhood. British Association for Paediatric Nephrology [J].Lancet, 1991, 337(8757): 1555-1557.
59
Abeyagunawardena AS, Hindmarsh P, Trompeter RS. Adrenocortical suppression increases the risk of relapse in nephrotic syndrome [J].Arch Dis Child, 2007, 92(7): 585-588.
60
Kane KF, Emery P, Sheppard MC, et al. Assessing the hypothalamopituitary-adrenal axis in patients on long-term glucocorticoid therapy: the short synacthen versus the insulin tolerance test [J].QJM, 1995, 88(4): 263-267.
61
Arun S, Bhatnagar S, Menon S, et al. Efficacy of zinc supplements in reducing relapses in steroid-sensitive nephrotic syndrome [J].Pediatr Nephrol, 2009, 24(8): 1583-1586.
62
Prasher PK, Varma PP, Baliga KV. Efficacy of enalapril in the treatment of steroid resistant idiopathic nephrotic syndrome [J]. J Assoc Physicians India,1999, 47(2): 180-182.
63
Bagga A, Mudigoudar BD, Hari P, et al. Enalapril dosage in steroid-resistant nephrotic syndrome [J]. Pediatr Nephrol, 2004,19(1): 45-50.
64
Yi Z, Li Z, Wu X C, et al. Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome [J]. Pediatr Nephrol, 2006, 21(7): 967-972.
65
Hodson EM, Habashy D, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children [J/CD]. Cochrane Database Syst Rev, 2009, 19(2): CD003594.
[1] 陶宏宇, 叶菁菁, 俞劲, 杨秀珍, 钱晶晶, 徐彬, 徐玮泽, 舒强. 右心声学造影在儿童右向左分流相关疾病中的评估价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 959-965.
[2] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[3] 严华悦, 刘子祥, 周少波. 磷酸烯醇式丙酮酸羧激酶-1在恶性肿瘤中的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 452-456.
[4] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[5] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[6] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[7] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[8] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[9] 公宇, 廖媛, 尚梅. 肝细胞癌TACE术后复发影响因素及预测模型建立[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 818-824.
[10] 李一帆, 朱帝文, 任伟新, 鲍应军, 顾俊鹏, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 纪卫政. 血GP73水平在原发性肝癌TACE疗效评价中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 825-830.
[11] 魏志鸿, 刘建勇, 吴小雅, 杨芳, 吕立志, 江艺, 蔡秋程. 肝移植术后急性移植物抗宿主病的诊治(附四例报告)[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 846-851.
[12] 中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-肛管癌(2024 版)[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 441-449.
[13] 吴天宇, 刘子璇, 杨浦鑫, 贾思明, 丁凯, 程晓东, 李泳龙, 陈伟, 吕红芝, 张奇. 腰椎间盘突出症保守治疗进展[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 379-384.
[14] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?